Revance shares drop after crow's-feet treatment study fails

Revance Therapeutics Inc. plummeted in the extended session Monday after a late-stage clinical study for the tiny biotech crow's-feet treatment did not reach its main goal. Revance shares dropped 27% to $13.44 after hours. The company said a study of its topical gel DaxibotulinumtoxinA did not significantly improve crow's feet, or branching wrinkles at the outer corners of the eyes, 28 days after treatment.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.